Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis
March 07, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
Higher-dose arm initiated in ongoing Phase 2 study following safety review by independent Data Monitoring Committee New Phase 2 study planned for patients who have one copy of the...
Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors
March 01, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., March 01, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with...
Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results
February 29, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
- Phase 2 Study Enrollment Progressing - Orphan Drug and Fast Track Designations Granted for N91115 in Cystic Fibrosis BOULDER, Colo., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics,...
Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis
February 18, 2016 16:05 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with...
Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis
January 15, 2016 11:16 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with...
Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
December 01, 2015 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics to Present at the Stifel Healthcare Conference 2015
November 10, 2015 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...
Nivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015
November 02, 2015 16:05 ET
|
Nivalis Therapeutics, Inc.
- N91115 Phase 1b Data Recently Presented at North American Cystic Fibrosis Conference - Phase 2 Study on Track to Enroll First Patient in Fourth Quarter BOULDER, Colo., Nov. 02, 2015 ...
Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial
October 07, 2015 16:10 ET
|
Nivalis Therapeutics, Inc.
- No dose limiting toxicities were observed and N91115 was well tolerated in the study- Data to be presented at the North American Cystic Fibrosis Conference BOULDER, Colo., Oct. 07, 2015 (GLOBE...
Nivalis Therapeutics to Present at Two Upcoming Investor Conferences
September 04, 2015 07:00 ET
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, today announced...